What is the future for biosimilars in the EU?
What issues do EU Payers think will impact adoption, pricing and reimbursement of biosimilars?
In January 2016 Samsung Bioepis launched Benepali, a biosimilar version of Enbrel marking a significant advance in biosimilar therapy options. With biosimilar versions of Avastin and Herceptin in the pipeline, the sector is on the verge of delivering lower cost yet equally effective medicines. Payers are enthusiastic about the savings biosimilars bring but warn that physician fear, stoked by a lack of data, clinical inexperience and misinformation, is limiting biosimilar uptake. As the market matures, expect wider clinical adoption and patient support, though questions around price discounting and substitution remain unresolved.
You're just a couple of clicks away from finding out Payers candid views of biosimilars. This report is available for immediate download after purchase -- buy your report now.
For a complete understanding turn to Biosimilars: European Payer Perspectives 2017, a report that reveals the latest insights of EU payers and the issues they see as being critical for the sector’s development. Buy the report now.
Report available for immediate download -- place your order today
Report available for immediate download -- place your order now
Spanish Payers:
Italian Payers:
“Obviously biosimilars are giving us significant cost savings because they are cheaper than the originator molecules with all the same indications. So certainly in my area, we are very pro biosimilars. But for us locally, the reason that we’ve been able to switch [to biosimilars] is because we’ve shared savings with secondary care commissions. It’s allowed us to develop the service and the feedback from patients is actually that it’s better than it was before because they’ve got more time, they are being monitored more closely and they just feel there are getting more out of the service than they were when they were on a branded product, indirectly, because we have invested the money back into the service.”
UK Payer
“Formulary inclusion has been quite quick, once the product has been authorised. In fact, I think it has accelerated a bit and it will be accelerated in the future too because the market is growing. So at the regulatory level, AIFA and EMA, they have accepted this market, which they looked at with misgivings before. The process has accelerated, because all the verification processes are streamlined.”
Italian Payer
“At this time it should be [the choice of physicians]. We need perhaps one or two more years to ensure that we don’t have a problem with safety, that we don’t have a problem in immunogenicity, for example. But after that, I think the pharmacists should be aware and should be able to switch like the generics.”
French Payer
Critical insights from these and many other respected experts available for immediate download —place your order here
Report available for immediate download — place your order now
This critical intelligence is available for immediate download — order your copy now
Need more information? Contact a consultant for an executive summary and sample pages from the report.
What is the future for biosimilars in the EU?
What issues do EU Payers think will impact adoption, pricing and reimbursement of biosimilars?
In January 2016 Samsung Bioepis launched Benepali, a biosimilar version of Enbrel marking a significant advance in biosimilar therapy options. With biosimilar versions of Avastin and Herceptin in the pipeline, the sector is on the verge of delivering lower cost yet equally effective medicines. Payers are enthusiastic about the savings biosimilars bring but warn that physician fear, stoked by a lack of data, clinical inexperience and misinformation, is limiting biosimilar uptake. As the market matures, expect wider clinical adoption and patient support, though questions around price discounting and substitution remain unresolved.
You're just a couple of clicks away from finding out Payers candid views of biosimilars. This report is available for immediate download after purchase -- buy your report now.
For a complete understanding turn to Biosimilars: European Payer Perspectives 2017, a report that reveals the latest insights of EU payers and the issues they see as being critical for the sector’s development. Buy the report now.
Report available for immediate download -- place your order now
Report available for immediate download -- place your order today
Spanish Payers:
Italian Payers:
“Obviously biosimilars are giving us significant cost savings because they are cheaper than the originator molecules with all the same indications. So certainly in my area, we are very pro biosimilars. But for us locally, the reason that we’ve been able to switch [to biosimilars] is because we’ve shared savings with secondary care commissions. It’s allowed us to develop the service and the feedback from patients is actually that it’s better than it was before because they’ve got more time, they are being monitored more closely and they just feel there are getting more out of the service than they were when they were on a branded product, indirectly, because we have invested the money back into the service.”
UK Payer
“Formulary inclusion has been quite quick, once the product has been authorised. In fact, I think it has accelerated a bit and it will be accelerated in the future too because the market is growing. So at the regulatory level, AIFA and EMA, they have accepted this market, which they looked at with misgivings before. The process has accelerated, because all the verification processes are streamlined.”
Italian Payer
“At this time it should be [the choice of physicians]. We need perhaps one or two more years to ensure that we don’t have a problem with safety, that we don’t have a problem in immunogenicity, for example. But after that, I think the pharmacists should be aware and should be able to switch like the generics.”
French Payer
Critical insights from these and many other respected experts available for immediate download —place your order now
Report available for immediate download — place your order here
This critical intelligence is available for immediate download —order your copy here
Need more information? Contact a consultant for an executive summary and sample pages from the report.
All Contents Copyright © 2019 Doctor's Guide Publishing Limited All Rights Reserved